Colorectal cancer statistics, 2023Rebecca L. Siegel, Ahmedin Jemal, Nikita Sandeep Wagle et al.|CA A Cancer Journal for Clinicians|2023Cited by 3.8k
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Heinz‐Josef Lenz, Kristen K. Ciombor et al.|The Lancet Oncology|2023Cited by 244
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancerMargherita Ambrosini, Filippo Pietrantonio, Benoı̂t Rousseau et al.|Annals of Oncology|2024Cited by 73
Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract CancerDarren Cowzer, James J. Harding, Madison Darmofal et al.|JCO Precision Oncology|2025Cited by 3
Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancerAhmed Mahmoud, Karuna Ganesh, Philip H. Choi et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0